Core Viewpoint - VolitionRx Limited has announced a public offering of 11,550,000 shares of common stock and warrants, aiming to raise approximately $6.0 million in gross proceeds before expenses [1][3]. Offering Details - The public offering price is set at $0.52 per share, with each warrant priced at $0.01, and an exercise price of $0.60 per share [1]. - The underwriter has a 30-day option to purchase an additional 1,732,500 shares and warrants to cover overallotments [2]. - If the warrants are fully exercised, the additional gross proceeds could reach approximately $6.9 million [3]. Use of Proceeds - The net proceeds from the offering will be utilized for research, product development, clinical studies, commercialization, working capital, and potential strategic acquisitions [4]. Company Overview - Volition is a multinational company focused on advancing epigenetics, aiming to improve early detection and monitoring of diseases [8]. - The company is developing cost-effective blood tests for various diseases, including certain cancers and conditions associated with NETosis [9]. - Research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [10].

Company Performance - Apogee Enterprises Inc. reported better-than-expected second-quarter financial results, with shares gaining 1.4% to $42.00 in after-hours trading [2] - Levi Strauss & Co. reported third-quarter earnings of 34 cents per share, exceeding the analyst consensus estimate of 31 cents per share, and quarterly sales of $1.543 billion, surpassing the estimate of $1.501 billion; however, shares fell 7.7% to $22.65 in after-hours trading [2] - VolitionRX Ltd. announced a public offering of common stock and common stock warrants, leading to a 20% dip in shares to $0.48 in after-hours trading [2] - USANA Health Sciences Inc. reported preliminary third-quarter results with an adjusted loss of 15 cents per share and sales of $214.00 million, resulting in an 11.4% decline in shares to $23.26 in after-hours trading [2] - Nurix Therapeutics Inc. reported worse-than-expected third-quarter financial results, causing shares to fall 5.7% to $10.24 in after-hours trading [2]

, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi- national epigenetics company, announced today that it is proposing to offer and sell, in an underwritten public offering, shares of its common stock and accompanying common stock purchase warrants. In addition, Volition intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock and warrants offered in the offering at the public offering price, l ...

PresentationYou may type in a question at any time during the webinar, you can do this through the Q&A panel, which appears on the right side of the webinar presentation. If you look to the bottom tray of your window, there is a series of widgets to enhance your webinar experience. And with that, I'll turn it over to Marielle.Great. Good morning, everyone. I'm Alexandra Byrne. I'm a reporter at GenomeWeb, and I will be your moderator for today's webinar. The title of today's webinar is beyond the genome: Me ...

Summary of the Webinar on Epigenetic Modifications for Biomarker and Drug Discovery Industry and Company Involved - **Industry**: Biotechnology focusing on epigenetic modifications and cancer diagnostics - **Companies**: Volition and HelioGenomics Core Points and Arguments 1. **Overview of Volition**: Volition is a multinational company with R&D labs in Belgium and the U.S., aiming to save lives through innovative diagnostic technologies [2][3] 2. **Nucleosomes and Epigenetic Modifications**: Nucleosomes, composed of DNA and histone proteins, undergo various post-translational modifications (PTMs) that regulate gene expression and are implicated in diseases like cancer [3][4] 3. **Nuclear Assays**: Volition's nuclear assays quantitatively measure circulating nucleosomes and their modifications, with a portfolio of 14 assays targeting specific epigenetic features [4][5] 4. **Diagnostic Potential**: H3K27 trimethylation levels were significantly elevated in non-small cell lung cancer (NSCLC) patients, showing a 3.7 to 2.9-fold increase compared to healthy controls, indicating its potential as a diagnostic biomarker [11][12] 5. **Prognostic Value**: Elevated levels of H3K27 trimethyl nucleosomes were associated with worse outcomes in NSCLC, with a hazard ratio of 3.56, suggesting its use as a prognostic biomarker [41] 6. **Combination with ctDNA**: Combining H3K27 trimethyl status with circulating tumor DNA (ctDNA) improved patient identification by 15.1%, enhancing the sensitivity of blood-based assays [13][50] 7. **EZH2 Inhibitors**: EZH2 inhibitors, such as ORIC-944, show promise in treating cancers by targeting the PRC2 complex, with ongoing clinical trials demonstrating their efficacy [16][17] 8. **Immunogenicity Enhancement**: EZH2 inhibition can increase tumor visibility to the immune system, enhancing the efficacy of immunotherapies by promoting T cell infiltration and activation [27][55] 9. **Clinical Trials**: Multiple clinical trials are investigating the combination of EZH2 inhibitors with immune checkpoint blockade therapies, indicating a strategic shift towards immunoepigenetic combinations [30][57] Other Important but Possibly Overlooked Content 1. **Assay Development Support**: Volition offers support for customizing assays tailored to specific drug programs and matrices, indicating a collaborative approach with pharmaceutical partners [54] 2. **Toxicity Detection**: The H3.1 nuclear assay can serve as an early indicator of systemic cell death, providing a sensitive method for detecting toxicity during drug development [42] 3. **Logistical Considerations**: Proper sample collection and processing are crucial for assay accuracy, with specific recommendations for handling plasma samples [48][58] 4. **Specificity of Assays**: The assays are designed to specifically detect intact circulating nucleosomes without cross-reactivity to other histone modifications [46][53] This summary encapsulates the key insights from the webinar, highlighting the advancements in epigenetic assays and their implications for cancer diagnostics and treatment.

Details of the Webinar: Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery Accessibility StatementSkip Navigation HENDERSON, Nev., Oct. 2, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the sponsorship of a GenomeWeb webinar entitled "Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery" on Wednesday, October 8 (details can b ...

Accessibility StatementSkip Navigation HENDERSON, Nev., Sept. 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with Hologic Diagenode ("Hologic") for the co-marketing of Volition's Nu.Q Discover service. The Nu.Q Discover service provides drug developers and scientists with a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and ...

Core Viewpoint - Biotech stocks are experiencing renewed momentum, with small-cap companies like Nautilus Biotechnology, PepGen, Lixte, RenovoRx, Genelux, and VolitionRx attracting investor interest through various catalysts such as insider buying, strategic partnerships, and clinical trial progress Group 1: Nautilus Biotechnology (NAUT) - Nautilus Biotechnology's stock surged 5.52% during regular trading, closing at $0.7070, and rose an additional 7.5% in after-hours trading to $0.76, with trading volume nearly double its average at 647,399 shares [2] - Recent insider buying by CEO Sujal M. Patel, who purchased 83,500 shares on September 8 and 116,500 shares on September 5, totaling over $135,000, indicates strong leadership confidence [3] - The company reported a narrower loss of $0.12 per share in Q2 2025, with an 18% drop in operating expenses, and has $179.5 million in cash, providing a financial runway through 2027 [4] Group 2: PepGen Inc. (PEPG) - PepGen's stock rebounded 7.14% in after-hours trading to $1.50 after a regular session close of $1.40, with trading volume more than double its average at 638,576 shares [4] - The company completed dosing for its 15 mg/kg arm of the FREEDOM trial, with topline data expected in early Q4 2025, following a strategic narrowing of its pipeline [5] Group 3: Lixte Biotechnology Holdings Inc. (LIXT) - Lixte's stock rose 5.85% in after-hours trading to $5.25 after closing at $4.96, with a trading volume of 503,604 shares, notable given recent volatility [5] - The company announced a $2.6 million purchase of Bitcoin and Ethereum to diversify its treasury holdings, reflecting a strategic shift in financial strategy [6] Group 4: RenovoRx Inc. (RNXT) - RenovoRx shares increased 4.22% in after-hours trading to $1.2194 after a regular session close of $1.17, with trading volume significantly above its average at 886,119 shares [6] - The company received a positive recommendation to continue its Phase III TIGeR-PaC trial for pancreatic cancer, reinforcing confidence in its lead therapy platform [7] Group 5: Genelux Corp. (GNLX) - Genelux's stock rose 4.11% in after-hours trading to $3.80 after closing at $3.65, with trading volume relatively light at 60,339 shares [8] - The recent activity follows Genelux's participation in the H.C. Wainwright Global Investment Conference [9] Group 6: VolitionRx Ltd. (VNRX) - VolitionRx's stock increased 4.27% in after-hours trading to $0.6474 after closing at $0.6209, with trading volume slightly below its average at 183,777 shares [10] - The company announced a Research License and Exclusive Commercial Option Rights Agreement with Werfen's Immunoassay Technology Center, focusing on advancing its Nu.Q NETs assay for Antiphospholipid Syndrome [10]

Core Insights - VolitionRx Limited has signed a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome (APS) with Werfen's Immunoassay Technology Center, a leader in specialized diagnostics [1][2][3] Company Overview - VolitionRx is a multi-national epigenetics company focused on advancing the science of epigenetics and developing cost-effective blood tests for early detection and monitoring of diseases [13][14] - Werfen is a family-owned company founded in 1966, specializing in diagnostics in areas such as Hemostasis and Autoimmunity, with worldwide sales of €2.2 billion in 2024 [12] Agreement Details - The agreement allows Werfen to access Volition's proprietary Nu.Q® H3.1 NETs assay to investigate its clinical utility in managing APS patients [3][4] - Werfen has the option to negotiate exclusive commercial rights for launching the product [3] Clinical Implications - APS affects approximately four million people globally and is associated with increased risks of blood clots and complications such as stroke and heart attack [5][10] - The Nu.Q® NETs test is being investigated as a potential biomarker for APS, which could improve diagnostic information and patient monitoring [7][8] Technological Advancements - Early results from the Nu.Q® NETs assay on Werfen's ACL AcuStar® platform show promising detection levels in APS patients [4] - The collaboration aims to validate the clinical utility of the Nu.Q® test as a risk indicator for thrombosis in APS patients [4][6]

Financial Data and Key Metrics Changes - Total operating expenses for Q2 2025 declined by 9% compared to 2024, primarily due to lower personnel and research and development costs [6] - Net cash used in operating activities was $6,300,000 for Q2 2025, down from $6,700,000 in 2024, with total cash used in operations for the first half of 2025 totaling $10,600,000, a 30% decrease year-over-year [6][7] - Revenue for Q2 2025 was over $400,000, bringing total revenue for the first half of 2025 to a little over $650,000, representing a 15% increase compared to the same period in 2024 [6][7] Business Line Data and Key Metrics Changes - The company recorded its first revenue from sales of a human product, Nu. Q Net, marking a significant milestone in its commercialization efforts [6] - The Nu. Q Cancer and Nu. Q Nets pillars have shown significant progress, with independent studies confirming the effectiveness of their biomarkers [9][14] - The Nu. Q Vet cancer test continues to expand globally, with supply agreements in place with leading industry players [34][35] Market Data and Key Metrics Changes - The total addressable market for cancer and sepsis diagnostics is estimated at approximately $25 billion annually, presenting substantial revenue opportunities for the company and its partners [21] - The potential market for the Nu. Q test in lung cancer screening could exceed $1 billion annually across Taiwan, the U.S., U.K., and France [24] Company Strategy and Development Direction - The company aims to achieve cash neutrality for the full year 2025 by executing licensing agreements with significant upfront payments and reducing expenditures [5] - The focus for 2025 is on commercializing the Nu. Q platform in the human diagnostic market, with ongoing discussions with over 10 companies [19][20] - The strategy includes leveraging existing CE Marked products for NETosis-related diseases while expanding into new markets through licensing agreements [26][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress in licensing discussions and the potential for significant revenue generation from upcoming deals [19][20] - The company is confident in the robustness and reliability of its platform, which has applications across various clinical areas, including cancer and sepsis [92] - Management anticipates that the next few quarters will be pivotal for securing licensing agreements and advancing commercialization efforts [42][92] Other Important Information - The company has made substantial progress in its clinical study programs, with ongoing collaborations and studies expected to yield further validation of its products [9][12] - The company is exploring co-marketing partnerships to enhance the reach of its Nu. Q Discover platform [41] Q&A Session Summary Question: Which uses of the Nu. Q platform have attracted the most attention from potential partners in the human health space? - Management indicated that interest spans across all areas, including Discover, NETosis, and oncology, with significant engagement from major diagnostic and pharmaceutical companies [46][49] Question: How will the company utilize capital from executed deals to drive revenues? - The company plans to use capital to achieve revenue neutrality and expects varying deal structures across different applications, with some anticipated to yield large payments and ongoing revenues [55][56] Question: Can details be provided on the first human deal's indication or application? - While specifics were not disclosed due to confidentiality, management emphasized that all deals will leverage the robust and reliable Nu. Q test [63][65] Question: What is the expected timeline from licensing a deal to commercialization? - The timeline varies, with immediate revenue possible for some deals, while others may take two to three years for regulatory approval [70][73] Question: Are there any regulatory bodies that need to approve the Taiwan screening program before full production? - Management confirmed that the current validation study is ongoing, and if successful, the test could be launched quickly in a clear lab setting [77][80]